24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
This research is testing a new medicine called LOU064 for teenagers aged 12 to 17 who suffer from chronic hives (Chronic Spontaneous Urticaria, or CSU). These are hives that appear often and haven't fully cleared up with standard allergy medications. The study aims to see if LOU064 can effectively reduce hives and itching, how safe it is to use, and how the body handles the medicine. Participants will first receive either the new medicine or a dummy treatment, and then many will have the option to continue receiving the medicine for a longer period. There will also be a follow-up period to check on participants' health after the medicine is stopped.
At a glance
What is this study about?
This study is designed to explore a new potential treatment, called LOU064, for teenagers between 12 and 17 years old who experience chronic hives. These are hives that appear without a clear cause and have lasted for at least six months, even after trying common allergy medications. The main goal is to find out if LOU064 is better than a dummy treatment (placebo) at reducing the itching and hives, and how well the body tolerates it.
Participants will begin in a 'core period' where they receive either LOU064 or a placebo for about 24 weeks. After this, many will have the option to enter an 'open-label extension' where everyone receives LOU064, provided the doctors think it's suitable. This longer period helps researchers understand the long-term effects of the medicine. There's also a final follow-up period to monitor health after treatment has finished.
The findings from this study are very important. They will help doctors understand if LOU064 could become a new, effective, and safe treatment option for young people struggling with chronic hives that haven't responded to existing medicines. This could significantly improve the quality of life for many teenagers, helping them manage their symptoms better.
Key takeaways
- This study is for teens (12-17) with persistent chronic hives.
- It tests a new medicine, LOU064, against a dummy pill (placebo).
- Participation involves regular visits and health checks over several months to years.
- The goal is to see if LOU064 is safe and effective for long-term use.
- You might receive the active medicine or a placebo in the first phase.
- You can stop participating at any time.
Who may be eligible?
To join this study, you must be a male or female teenager aged between 12 and 17. You need to have had chronic hives (urticaria) for at least six months, and these hives shouldn't have improved enough even though you've been taking standard allergy pills (H1-antihistamines) as advised by your doctor. You also need to have experienced hives and itching frequently in the weeks leading up to the study, and these symptoms will be measured during the screening process.
There are also reasons why you wouldn't be able to join. For example, if you've already taken this specific experimental medicine or similar ones before. You also can't participate if you have certain health conditions like a significant risk of bleeding, a history of serious stomach bleeding, or specific heart, liver, or kidney problems. If you're allergic to any of the study medicines or similar types, or if your hives have a clear, single trigger (like a specific allergy to something), then you wouldn't be able to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you between 12 and 17 years old?
- Have you had chronic hives for at least 6 months?
- Have your hives not improved enough with regular allergy medicines?
- Do you currently have frequent itching and hives?
- Have you never taken this specific new medicine (LOU064) or similar ones?
- Do you have good overall health without major bleeding risks or liver/heart issues?
What does participation involve?
If you join this study, it will be split into three main parts. First, for about 32 weeks, you'll be in the 'core period' where you'll visit the study site about 10 times. During this time, you'll receive either the study medicine (LOU064) or a dummy treatment (placebo) – you won't know which one. This is followed by an optional 'open-label extension' which could last from one year up to three years, with 3 to 15 visits depending on your hives. In this part, if your doctor agrees, you'll receive LOU064. Finally, there's an optional 'long-term follow-up' for three years, with one visit and up to four phone calls, where you won't receive any treatment but will be monitored for your health. The total time you could be involved in the study ranges from about 8 months to over 6 years.
Potential risks and benefits
Locations (65)
- Kern ResearchVerified postcodeBakersfield, United States· Recruiting
- Allergy and Asthma Medical Group and Research CenterVerified postcodeSan Diego, United States· Recruiting
- Pediatric Dermatology of Miami at the Pediatric CoEVerified postcodeMiami, United States· Recruiting
- Treasure Valley Medical ResearchVerified postcodeBoise, United States· Active not recruiting
- Endeavor HealthVerified postcodeGlenview, United States· Active not recruiting
- Allergy and Asthma Specialist P S CVerified postcodeOwensboro, United States· Recruiting
- Toledo Institute of Clinical ResearchVerified postcodeToledo, United States· Recruiting
- Allergy Asthma and Clinical ResearchVerified postcodeOklahoma City, United States· Recruiting
- Allergy and Clinical Immunology AssociatesVerified postcodePittsburgh, United States· Active not recruiting
- RFSA DermatologyVerified postcodeSan Antonio, United States· Recruiting
- Allergy Associates of UtahVerified postcodeSandy City, United States· Completed
- Seattle Allergy and Asthma RschVerified postcodeSeattle, United States· Withdrawn
Common questions
What are 'chronic spontaneous urticaria' (CSU)?
CSU refers to hives that appear regularly for at least six weeks, without a clear trigger, and can be very itchy.
What is a 'placebo'?
A placebo is a dummy treatment that looks just like the real medicine but contains no active drug. It helps researchers compare the real medicine's effects.
What does 'double-blind' mean?
It means that neither you nor your study doctor will know whether you are receiving the real medicine (LOU064) or the placebo.
How long will I be in the study overall?
The study could last from about 8 months up to over 6 years, depending on which optional parts you choose to join.
Can I leave the study at any time?
Yes, you are free to leave the study at any point, and doing so will not affect your future medical care.
How to find out more
Novartis Pharmaceuticals
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.